Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH in the ATM Prospectus

<< Previous

Bullboard Posts

Next >>

Comment by Bucknelly21on Aug 19, 2021 10:12pm

112 Views

Post# 33738084

RE:RE:RE:RE:NASH in the ATM Prospectus

Wino115 wrote: I see ok well that makes more sense
My recollection is they said it was the 6 person scientific committee that introduced the idea and they, the BOD, Grinspoon, Mgmt pushed for it with FDA allowing it eventually. Recall there was a UK, French,German,and Canadian doctors along with some US. Mix of HIV and liver specialists.

Bucknelly21 wrote: Good question because they said fda said go for general Nash